Executive Summary

The PD-1 and PD-L1 product landscape is best understood as a mature oncology platform rather than a single-product market. Pembrolizumab remains the dominant commercial product, nivolumab remains the major second PD-1 franchise, and PD-L1 products such as durvalumab and atezolizumab continue to anchor clinically meaningful segments of lung, bladder, hepatobiliary, and other oncology use.

The class has shifted from advanced-disease immunotherapy toward broader treatment architecture. Current strategic value is increasingly tied to earlier-line use, perioperative regimens, biomarker-defined populations, fixed-dose or subcutaneous lifecycle extensions, and rational combinations with chemotherapy, anti-CTLA-4 therapy, targeted therapy, antibody-drug conjugates, and radiotherapy.

For economic analysis, the article separates annual worldwide manufacturer net sales from partial-period run-rate context and from U.S. public-payer spending. Solid revenue lines in the figure represent annual worldwide manufacturer net sales, while open markers represent annualized quarterly run-rates. This visual convention avoids implying that Q4 2025 or Q1 2026 markers are completed annual revenue values.